Page 13 - Query Get News Today

Suicide risk prediction in adults was optimized when utilizing both in-person screening and electronic data, according to a study published in JAMA Network Open. “Mental health diagnoses are often absent in records of those who subsequently die from suicide. Better risk identification and prognostication might improve outreach and prevention,” Drew Wilimitis, BS, of the department of

The addition of isatuximab-irfc to carfilzomib and dexamethasone conferred a durable PFS benefit to patients with relapsed multiple myeloma, according to updated results of the randomized phase 3 IKEMA trial.“These results show an unprecedented median PFS of 3 years [among patients who received the three-agent regimen],” Philippe Moreau, MD, head of the department of hematology at

Almirall S.A. and Inserm Transfert have entered an agreement to advance research in vitiligo treatment, the two entities announced in a press release.The licensing and research collaboration agreement will focus on developing medicines that modulate the Wnt pathway.

Bon Secours Mercy Health and Strive Health have entered a collaborative relationship to provide “high-quality, whole-person care” for patients with kidney disease.According to the press release, Strive Health intends to offer comprehensive support to Bon Secours Mercy Health to achieve the goal of helping nearly 8,000 patients with chronic kidney disease and end-stage kidney disease

SAN FRANCISCO — A session at the American Thoracic Society International Conference highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults. The new guidance comes nearly 4 years after the last guidance on the diagnosis and management of IPF, according to the ATS.

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.Similar treatment-related toxicities occurred regardless of patients’ race or ethnicity, findings published in Bone Marrow Transplantation showed.

The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.

Travere Therapeutics Inc. announced the FDA has accepted and granted priority review of its new drug application under subpart H for accelerated approval of sparsentan for treatment of IgA nephropathy.According to the company press release, sparsentan is a dual endothelin angiotensin receptor antagonist that targets the endothelin A receptor and the angiotensin II subtype 1 receptor.

FORT LAUDERDALE, Fla. — Susvimo was noninferior to monthly ranibizumab and provided comparable vision and controlled retinal thickness through 96 weeks, according to data from the Archway trial.At the Retina World Congress, Aleksandra Rachitskaya, MD, presented end-of-study results from the phase 3 trial, which explored the safety and efficacy of Susvimo (ranibizumab injection, Genentech)

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.An independent data monitoring committee recommended the randomized phase 3 CheckMate -901 trial continue to allow for assessment of other primary and secondary endpoints.